Chronic Hepatitis B: Interpretation and Applications of Quantitative HBsAg as a Clinical Tool
Overview
Discover how advancements in quantitative hepatitis B surface antigen (qHBsAg) testing are reshaping the management of chronic hepatitis b (CHB). In this GSK-sponsored program, experts will share practical insights, real-world perspectives, and emerging evidence on functional cure and the clinical utility of qHBsAg testing.
Learning objectives
At the end of this medical education program, participants will be able to:
- Explain the biologic significance and role of HBsAg in CHB.
- Identify clinical scenarios where Quantitative HBsAg may inform CHB management.
- Apply qHBsAg data to case-based CHB decision-making and patient counseling.
Key dates
- Released date:
- Aug. 17, 2026
- Expiration date:
- Aug. 17, 2027
Pricing
Agenda
All times are Eastern.
Session Heading 1: Lorem Ipsum Dolor sit Amet
10:00 a.m. - 5:00 p.m.
Session Sub-title 1
Person, PhD
10:00 - 11:00 a.m.
Session Sub-title 2
Person, PhD
11:00 - 12:00 midday
Session Sub-title 3
Person, PhD
12:00 - 1:00 p.m.
Session Heading 2: Lorem Ipsum Dolor sit Amet
10:00 a.m. - 5:00 p.m.
Session Sub-title 1
Person, PhD
10:00 - 11:00 a.m.
Session Sub-title 2
Person, PhD
11:00 - 12:00 midday
Session Sub-title 3
Person, PhD
12:00 - 1:00 p.m.
Course contents
Video
57 mins
Evaluation
Course faculty
Faculty
Patrick Horne, MSN, APRN, FNP-BC, AF-AASLD
Assistant Director of Clinical Hepatology Research/Clinical Programs Coordinator
University of Florida
Division of Gastroenterology, Hepatology, and Nutrition
Section of Hepatobiliary Diseases
Steven Han, MD, AGAF, FAASLD
Philip L. Palumbo
Professor of Clinical Hepatology
Program Director, Transplant Hepatology Fellowship
Clinical Professor of Medicine and Surgery
David Geffen School of Medicine at UCLA